In der Folge eines Status epilepticus entwickelt sich häufig eine chronische Epilepsie. In der vorliegenden Dissertation wurde die Fragestellung bearbeitet, ob ein Inhibitionsverlust im Gyrus dentatus Grundlage der Epileptogenese nach Status epilepticus ist. Ein selbst-erhaltender Status epilepticus (SSSE) wurde an erwachsenen Ratten durch elektrische Stimulation ausgelöst. Das Auftreten spontaner epileptischer Anfälle wurde im Verlauf von acht Wochen nach Status epilepticus zu drei Zeitpunkten (1, 4 und 8 Wochen) mittels Videoüberwachung erfasst. Zu denselben Zeitpunkten und vor Status epilepticus wurden elektrophysiologische Messungen im Gyrus dentatus durchgeführt. Die Aktivität der Prinzipalzellen des Gyrus dentatus unterliegt unter physiologischen Bedingungen einer ausgeprägten inhibitorischen Kontrolle. Durch Analyse von Doppelreizantworten wurden Veränderungen der Inhibition in dieser für die Epileptogenese relevanten Hirnstruktur beurteilt. Im Verlauf von acht Wochen nach SSSE entwickelte sich bei einem Großteil der Versuchstiere eine chronische Epilepsie. Zum spätesten Beobachtungszeitpunkt traten rekurrente spontane epileptische Anfälle bei 80 Prozent der Tiere auf. Die Inhibition im Gyrus dentatus war eine Woche nach Status epilepticus signifikant reduziert. Vier und acht Wochen nach SSSE zeigte sich eine zunehmende Wiederannäherung an die vor dem Status epilepticus erhobenen Messwerte, so dass von einem transienten Inhibitionsverlust im Gyrus dentatus nach Status epilepticus gesprochen werden kann. Zusammenfassend konnte in der Dissertation gezeigt werden, dass sich in der Folge eines Status epilepticus bei der Mehrzahl der Tiere eine chronische Epilepsie entwickelt. Der Inhibitionsverlust im Gyrus dentatus war zu einem Zeitpunkt am größten, da noch keine spontanen epileptischen Anfälle auftraten. Als sich bei den meisten Tieren eine chronische Epilepsie entwickelt hatte, war die Inhibition komplett wiederhergestellt. Daher ist ein Inhibitionsverlust im Gyrus dentatus nach einem Status epilepticus nicht der führende pathophysiologische Mechanismus für die Entwicklung einer chronischen Epilepsie. / Development of chronic epilepsy as a consequence of status epilepticus is a frequent clinical observation. The aim of this work was to test the hypothesis that epileptogenesis after status epilepticus depends on a loss of inhibitory function in the dentate gyrus. A self-sustaining status epilepticus (SSSE) was induced in rats by continuous electrical stimulation of the perforant path. The occurrence of spontaneous epileptic seizures was assessed by video monitoring 1, 4 and 8 weeks after SSSE. At the same time points and directly before SSSE, inhibition in the dentate gyrus was measured using a paired pulse paradigm. In this region, excitability of principal cells is under physiological conditions effectively controlled by the activity of inhibitory interneurons. In addition, the dentate gyrus is relevant for the process of epileptogenesis due to anatomical properties. In the time course after SSSE, the fraction of animals showing spontaneous epileptic seizures increased steadily reaching 80 % after eight weeks. One week after SSSE, inhibition in the dentate gyrus was significantly reduced. This loss proved to be transient, as inhibition recovered after 4 weeks and reached pre-status values after 8 weeks. In conclusion, the majority of animals developed chronic epilepsy as a consequence of status epilepticus. Loss of inhibition in the dentate gyrus was maximal while spontaneous seizures had not yet developed. Inhibition was normalized when most animals had become epileptic. Thus, loss of inhibition in the dentate gyrus following status epilepticus is not a decisive mechanism in the emergence of spontaneous seizures.

[Truncated abstract] Formation and consolidation of the retinotectal projection during optic nerve regeneration has been associated with two major interlinked processes. Initially, retinal ganglion cell (RGC) axons are guided by molecular guidance cues, such as the Eph receptor tyrosine kinases and their ligands, the ephrins, to their approximately correct location and form a coarse topographic map in the optic tecum. Such axon guidance occurs in the absence of neural activity and is considered to be activity-independent. The second process involves glutamatergic excitation, whereby correctly located connections are strengthened by correlated neural activity, whilst removing inappropriately located ones thereby sharpening the topography.The second process is considered to be activitydependent. Here, a number of experiments were undertaken to further examine the interrelationships of activity-dependent and independent processes with respect to functional outcomes. Two models of optic nerve regeneration were studied. In goldfish, following optic nerve crush, regeneration is successful. … In goldfish, guidance along the medio-lateral tectal axis may occur through preordering of axons prior to entering the tectum via the appropriate medial and lateral brachium, with EphA/ephrin-A then guiding axons over the rostral-caudal axis establishing gross topography. The increase in involvement of NMDA-mediated transmission during the period of activity-dependent refinement consolidated the role of this receptor in synapse plasticity. However what triggers NMDA-mediated activity to increase is still largely unresolved, although as the factors governing receptor trafficking during development and synaptic plasticity become better understood, these can be applied to the period of plasticity associated with regenerating axons. And finally, as GABAergic inhibition appears to suppress activity-dependent refinement, means of overcoming this inhibition through 4 such methods as visual training or pharmacological intervention may have significance for mammalian regeneration.

Submitted by Marlene Santos (marlene.bc.ufg@gmail.com) on 2018-08-16T17:44:08Z No. of bitstreams: 2 Dissertação - Michelle Mendanha Mendonça - 2017.pdf: 20722346 bytes, checksum: 2ee7a850badae565954ebdb18346c83d (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2018-08-17T11:31:06Z (GMT) No. of bitstreams: 2 Dissertação - Michelle Mendanha Mendonça - 2017.pdf: 20722346 bytes, checksum: 2ee7a850badae565954ebdb18346c83d (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2018-08-17T11:31:06Z (GMT). No. of bitstreams: 2 Dissertação - Michelle Mendanha Mendonça - 2017.pdf: 20722346 bytes, checksum: 2ee7a850badae565954ebdb18346c83d (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2017-07-25 / Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq / Within the hypothalamic areas involved in the control of cardiovascular function, neurons of the paraventricular hypothalamus play a key role, either by projecting to the sympathetic premotor neurons of rostroventrolateral medulla (RVLM) or by reaching preganglionic neurons of the spinal intermediolateral column (IML). Despite describing the role of PVH in the cardiovascular control, literature lacks of data on the PVH contribution to the control of cardiac function. In this regard, the aim of the present study was to assess whether gabaergic and adrenergic synapses, known for being active at the PVH, are involved in the control of cardiac function by its neurons in normotensive anesthetized animals. Experiments were performed in adult male Wistar rats (250-350g) that were anesthetized with urethane (1.2-1.4 g/kg i.p.) and underwent catheterization of femoral to record arterial pressure and heart rate. Femoral vein was used to inject the vasoactive drugs phenylephrine (10μg/kg) the sodium nitroprussiate (10μg/kg), the blocker of cardiac pacemaker zatebradine (1mg/kg) and to supplement anesthesia. The cardiac left ventricle was catheterized to record the left ventricular pressure and its derivative. Craniotomy allowed for injections into the PVH of: muscimol (20mM – 100nL), bicuculline (0,4mM - 100nL), propranolol (10mM – 100nL), isoproterenol (100μM – 100nL), fentolamine (13mM – 100nL), phenylephrine (30nM – 100nL). The main results were: i) inhibition of PVH by injecting GABAA agonist muscimol, reduced arterial pressure and cardiac inotropy; ii) disihibition of PVH neurons by injecting bicuculline evoked positive chronotropy and inotropy; iii) Alfa adrenergic receptors control cardiac function; iv) Beta adrenergic receptors of PVH do not influence cardiac function; v) afterload seems to poorly contribute to the PVH-evoked inotropy. Jointly, our results suggest that PVH provides substantial contribution to the tonic control of cardiac function. We conclude that the PVH participates in the control of cardiac function. Changes in the activity of these neurons by gabaergic and adrenergic influences may set autonomic control of cardiac function, thus resulting in contractile and heartbeat responses. Deepen the knowledge on the mechanisms underlying the control of central areas and its influence on the cardiovascular system may feed the understanding of cardiovascular pathophysiology. / Dentre as áreas hipotalâmicas envolvidas no controle da função cardiovascular, os neurônios do hipotálamo paraventicular (PVH) desempenham um papel fundamental no controle da função cardíaca por meio de suas projeções para neurônios pré-motores simpáticos do bulbo rostroventrolateral (RVLM) pelas projeções diretas que alcançam os neurônios pré-ganglionares da coluna intermediolateral espinhal (IML). Contudo, não há dados na literatura sobre sua contribuição para o controle da função cardíaca em animais normotensos e anestesiados. Sendo assim, o objetivo do presente estudo foi avaliar se as sinapses gabaérgicas e adrenérgicas, presentes no PVH, estão envolvidas no controle da função cardíaca por esses neurônios. Os experimentos foram realizados em ratos Wistar machos (250-350g), que foram anestesiados com uretana (1,2 a 1,4 g / kg i.p.) e tiveram sua artéria femoral canulada para registrar pressão arterial e frequência cardíaca. A veia femoral foi utilizada para injeções de fármacos vasoativos fenilefrina (10μg/kg) e nitroprussitato de sódio (10μg/kg), do bloqueador do marcapasso cardíaco zatebradina (1mg/kg) e para suplementação de anestesia. O ventrículo esquerdo cardíaco foi cateterizado para medir a pressão ventricular esquerda e sua derivativa. A craniotomia foi realizada para permitir injeções no PVH de: muscimol (20mM – 100nL), bicucullina (0,4mM - 100nL), propranolol (10mM – 100nL), isoproterenol (100μM – 100nL), fentolamina (13mM – 100nL), fenilefrina (30nM – 100nL). Os principais achados deste estudo são: i) A inibição dos neurônios do PVH pela injeção do agonista GABAA muscimol reduziu a pressão arterial e o inotropismo cardíaco; ii) A desinibição dos neurônios do PVH pela injeção de bicuculina provocou respostas cronotrópicas e inotrópicas positivas; iii) Os receptores α-adrenérgicos contribuem para o cronotropismo e inotropismo cardíacos; iv) Os receptores β- adrenérgicos do PVH não influenciam o controle da função cardíaca; v) A pós-carga exerceu pouca influência nas respostas inotrópicas controladas pelo PVH. Em conjunto, os resultados sugerem que o PVH contribui de forma relevante para o controle tônico da função cardíaca em animais normotensos e anestesiados. Assim conclui-se que o PVH participa do controle da função cardíaca.

Cette thèse a pour objectif spécifique d’explorer les événements précoces pouvant être à l’origine du bourgeonnement aberrant des fibres moussues (FM) du gyrus denté, une réorganisation majeure dans l’Epilepsie du Lobe Tempora (ELT). Nous avons utilisé le modèle pilocarpine d’ELT chez le rat afin de montrer que la transmission GABAergique jouait un rôle prépondérant dans la formation des FM aberrantes au cours de l’épileptogenèse. Ceci étant due à une altération de l’homéostasie chlore, suite à une augmentation de l’expression du co-transporteur NKCC1 et une diminution du co-transporteur KCC2. Nos résultats ont démontré que le récepteur aux neurotrophines p75NTR était un médiateur de l’action trophique de la réponse GABAergique dépolarisante sur le bourgeonnement aberrant des FM. Le blocage de l’action dépolarisante de la transmission GABAergique via l’utilisation de la bumétanide, a permis de réduire le bourgeonnement aberrant des MF en réduisant l’expression de p75NTR. Enfin, l’application transitoire de la bumétanide au cours de l’épileptogenèse a abouti à la réduction du nombre de crises récurrentes et spontanées au cours de la phase chronique d’ELT chez le rat. Ce travail a permis de dévoiler les mécanismes moléculaires sous-jacents de la réorganisation du réseau neuronal glutamatergique consécutif à une crise inaugurale dans un modèle d’ELT. Dans l'ensemble, cette thèse apporte un éclairage nouveau sur l’importance de l’interaction de la signalisation GABAergique avec les neurotrophines afin d’orchestrer la plasticité réactive au sein de l’hippocampe dans TLE. / The present dissertation undertakes to investigate the early triggering events of the mossy fiber sprouting (MFS) in the dentate gyrus, a hallmark of hippocampal reactive plasticity in Temporal Lobe Epilepsy (TLE). We used the rat pilocarpine model of TLE to show that altered GABAA receptor-mediated transmission play a key role in the formation of early ectopic MFS during epileptogenesis. This is likely due to a compromised chloride homeostasis, as a result of increased expression of chloride loader NKCC1 and downregulation of the neuronal chloride extruder KCC2. We next addressed the mechanistic action of depolarizing GABAAR responses with regard to neurotrophin signaling. Our findings uncovered that the pan neurotrophin receptor p75 (p75NTR) mediated the sculpting action of depolarizing GABAAR responses on the ectopic MFS. Blockade of depolarizing GABAAR responses using the loop diuretic bumetanide reduced abnormal p75NTR subsequently decreased the ectopic MFS. Finally, transitory application of bumetanide during epileptogenesis resulted in reduction of spontaneous and recurrent seizures during the chronic phase of TLE. The rationale of this work is that unveiling the molecular mechanisms underlying the hippocampal post-seizure glutamatergic network rewiring will help to drive future novel therapeutic avenues involving chloride homeostasis and neurotrophin interplay. Overall, this dissertation shed a new light on how GABAergic transmission and neurotrophin signaling crosstalk can orchestrate reactive hippocampal plasticity in TLE.

La maladie d’Alzheimer est une maladie neurodégénérative déterminée par deux caractéristiques : les plaques extracellulaires composées d’amyloïde-β et l’accumulation intracellulaire de tau hyperphosphorylée, appelée enchevêtrements neurofibrillaires. Malgré le nombre important d’études, la nature de la toxicité des espèces tau hyperphosphorylée et hypophosphorylée reste mal connue. Notre projet de recherche vise à caractériser quel état de phosphorylation de la tau contribue le plus à la toxicité neuronale ainsi que d’identifier les mécanismes sous-jacents. Pour répondre à ces objectifs, nous avons généré des modèles transgéniques de C. elegans exprimant soit une tau hyperphosphorylée humaine (12 glutamates pour mimer l’hyperphosphorylation de la tau trouvée chez des patients Alzheimer), une tau sauvage, ou une tau hypophosphorylée (12 alanines pour mimer l’hypophosphorylation), dans les motoneurones GABAergiques. Ensuite, pour caractériser nos modèles, nous avons mesuré leur comportement principalement avec des tests de locomotion en utilisant le logiciel WormLab. Nos résultats ont montré que la tau phosphorylée est l’espèce la plus toxique car la souche hyperP a montré une perturbation du système locomoteur se traduisant par une neurodégénérescence ainsi que des problèmes développementaux (longueur des vers). Puis nous avons testé certains médicaments utilisés dans des modèles de tauopathies, afin d’identifier des voies biologiques impliquées dans la toxicité de la tau hyperphosphorylée. Pour conclure, nos modèles vont être des outils utiles pour identifier des modificateurs génétiques et pharmacologiques dans la toxicité de la tau. / Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by two hallmarks: extracellular plaques composed of amyloid-β (Aβ) deposits and intraneuronal accumulation of hyper and abnormal phosphorylated tau, also called neurofibrillary tangles (NFT). Despite many decades of research, the nature hypophosphorylated or hyperphosphorylated Tau toxicity remains ill understood. Our research project aims to characterize which state of Tau phosphorylation contributes to neuronal toxicity and identify the underlying mechanisms. To assess these objectives, we generated transgenic C. elegans models expressing either a human hyperphosphorylated tau (incorporation of 12 glutamate residues to mimic Tau hyperphosphorylation found in AD’s patients) human wild type Tau, or a human hypophosphorylated tau (incorporation of 12 alanine residues to mimic Tau hypophosphorylation) in the GABAergic motoneurons. Then, to characterize our models, we measured their behavior mainly with locomotion’s test using WormLab software. Our results showed that hyperphosphorylation of tau is the most toxic species for our models because hyperP strain showed an impair in the locomotor system translating into neurodegeneration, as well as developmental problems such as worm length. Then we tested some drugs used in taupathies C. elegans models to see if we could identify some biological pathways implicated in the toxicity. To conclude, our models may be a useful tool to identify genetic and pharmacological modifiers of tau toxicity.

京都大学 / 新制・課程博士 / 博士(医学) / 甲第24505号 / 医博第4947号 / 新制||医||1064(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 渡邉 大, 教授 林 康紀, 教授 井上 治久 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

The main aim of the thesis was to measure antidepressant (AD) non-compliance, to determine which factors are closely associated with AD non-compliance and the consequences of prolonged AD non-compliance in the private health sector of South Africa. The empirical study followed an observational, prospective, cohort study using longitudinal medicine claims data provided by a nationally representative Pharmaceutical Benefit Management company (PBM) from 1 January 2006 to 31 December 2011. Failure to respond to AD treatment and achieving remission has severe neurobiological and clinical consequences. The clinical consequences include increased social and functional impairment, higher risk for recurrence and relapse of a depressive episode, a weak treatment outcome, significant increase in treatment cost, over-utilization of health care systems, and ultimately an increased suicide risk. However, the neurobiological consequences are much more far reaching. One of the more serious yet under-recognized neurobiological complications of AD non-compliance is the development of antidepressant discontinuation syndrome (ADS), which is the result of non-compliance or the abrupt discontinuation of AD treatment. Altered serotonergic dysfunction appears central to ADS so that how an antidepressant targets serotonin will determine its relative risk for inducing ADS and thereby affect later treatment outcome. Low ADS risk with agomelatine versus other antidepressants can be ascribed to its unique pharmacokinetic characteristics as well as its distinctive actions on serotonin, including melatonergic, monoaminergic and glutamatergic-nitrergic systems. After the first four months only 34% (n=12 397) of patients were compliant. What’s more a statistically significant association was found between active ingredient consumed and compliance (p < 0.0001). Only 26.2% of patients who received amitriptyline-containing products were complaint compared to 38.8% and 38.7% in the cases of venlafaxine and duloxetine, respectively. The current study found that females have a significantly higher prevalence of MDD and HIV/AIDS when compared to males. The co-morbidity between HIV/AIDS and major depressive disorder (MDD) had a significant effect on AD treatment compliance as patients diagnosed with both HIV/AIDS and MDD (74.43. ± 32.03, 95%Cl: 71.51-77.34) displayed a lower compliance vs. MDD patients (80.94% ± 29.44, 95%Cl: 80.56-81.33). Noteworthy, observations were that 75% (p < 0.0217; Cramer’s V = 0.0388) of venlafaxine and 28.6% (p < 0.0197; Cramer’s V = -0.0705) of the paroxetine items were compliant in patients diagnosed with both HIV/AIDS and MDD. The overall compliance (35.19% acceptable compliance; n = 42 869) of patients taking both ADs and GDs was weak. In the group receiving both AD and GDs, an increased AD treatment period was associated with a significant increase (p < 0.0001) in AD compliance (406.60 days; 95%Cl: 403.20 – 409.90 vs. 252.70 days; 95%Cl: 250.20 – 255.20). In this cohort amitriptyline (29.57%), mirtazapine (31.36%) and fluoxetine (32.29%) were associated with the lowest levels of compliance, while duloxetine (40.67%) was found to have the highest compliance. Lastly, ADs with highest non-compliance were associated with an increase use in GDs. Alprazolam (n = 10 201) and zolpidem (n = 9 312) were the most frequently dispensed GDs in combination with AD treatment. In conclusion the current study confirms that AD non-compliance is as big an obstacle in developing countries as it is in developed countries. Antidepressant treatment non-compliance has far reaching consequences especially with the development of ADS which further complicates MDD and might be a precursor for the development of TRD. Several factors were found to be closely associated with AD treatment non-compliance which include; pharmacological class of AD, gender, chronic co-morbid illnesses and a short treatment period. / PhD (Pharmacy Practice), North-West University, Potchefstroom Campus, 2015

The main aim of the thesis was to measure antidepressant (AD) non-compliance, to determine which factors are closely associated with AD non-compliance and the consequences of prolonged AD non-compliance in the private health sector of South Africa. The empirical study followed an observational, prospective, cohort study using longitudinal medicine claims data provided by a nationally representative Pharmaceutical Benefit Management company (PBM) from 1 January 2006 to 31 December 2011. Failure to respond to AD treatment and achieving remission has severe neurobiological and clinical consequences. The clinical consequences include increased social and functional impairment, higher risk for recurrence and relapse of a depressive episode, a weak treatment outcome, significant increase in treatment cost, over-utilization of health care systems, and ultimately an increased suicide risk. However, the neurobiological consequences are much more far reaching. One of the more serious yet under-recognized neurobiological complications of AD non-compliance is the development of antidepressant discontinuation syndrome (ADS), which is the result of non-compliance or the abrupt discontinuation of AD treatment. Altered serotonergic dysfunction appears central to ADS so that how an antidepressant targets serotonin will determine its relative risk for inducing ADS and thereby affect later treatment outcome. Low ADS risk with agomelatine versus other antidepressants can be ascribed to its unique pharmacokinetic characteristics as well as its distinctive actions on serotonin, including melatonergic, monoaminergic and glutamatergic-nitrergic systems. After the first four months only 34% (n=12 397) of patients were compliant. What’s more a statistically significant association was found between active ingredient consumed and compliance (p < 0.0001). Only 26.2% of patients who received amitriptyline-containing products were complaint compared to 38.8% and 38.7% in the cases of venlafaxine and duloxetine, respectively. The current study found that females have a significantly higher prevalence of MDD and HIV/AIDS when compared to males. The co-morbidity between HIV/AIDS and major depressive disorder (MDD) had a significant effect on AD treatment compliance as patients diagnosed with both HIV/AIDS and MDD (74.43. ± 32.03, 95%Cl: 71.51-77.34) displayed a lower compliance vs. MDD patients (80.94% ± 29.44, 95%Cl: 80.56-81.33). Noteworthy, observations were that 75% (p < 0.0217; Cramer’s V = 0.0388) of venlafaxine and 28.6% (p < 0.0197; Cramer’s V = -0.0705) of the paroxetine items were compliant in patients diagnosed with both HIV/AIDS and MDD. The overall compliance (35.19% acceptable compliance; n = 42 869) of patients taking both ADs and GDs was weak. In the group receiving both AD and GDs, an increased AD treatment period was associated with a significant increase (p < 0.0001) in AD compliance (406.60 days; 95%Cl: 403.20 – 409.90 vs. 252.70 days; 95%Cl: 250.20 – 255.20). In this cohort amitriptyline (29.57%), mirtazapine (31.36%) and fluoxetine (32.29%) were associated with the lowest levels of compliance, while duloxetine (40.67%) was found to have the highest compliance. Lastly, ADs with highest non-compliance were associated with an increase use in GDs. Alprazolam (n = 10 201) and zolpidem (n = 9 312) were the most frequently dispensed GDs in combination with AD treatment. In conclusion the current study confirms that AD non-compliance is as big an obstacle in developing countries as it is in developed countries. Antidepressant treatment non-compliance has far reaching consequences especially with the development of ADS which further complicates MDD and might be a precursor for the development of TRD. Several factors were found to be closely associated with AD treatment non-compliance which include; pharmacological class of AD, gender, chronic co-morbid illnesses and a short treatment period. / PhD (Pharmacy Practice), North-West University, Potchefstroom Campus, 2015

Le fonctionnement du cortex cérébral nécessite l’action coordonnée de deux des sous-types majeurs de neurones, soient les neurones à projections glutamatergiques et les interneurones GABAergiques. Les interneurones GABAergiques ne constituent que 20 à 30% des cellules corticales par rapport au grand nombre de neurones glutamatergiques. Leur rôle est toutefois prépondérant puisqu’ils modulent fortement la dynamique et la plasticité des réseaux néocorticaux. Il n’est donc pas surprenant que les altérations de développement des circuits GABAergiques soient associées à plusieurs maladies du cerveau, incluant l’épilepsie, le syndrome de Rett et la schizophrénie. La compréhension des mécanismes moléculaires régissant le développement des circuits GABAergiques est une étape essentielle menant vers une meilleure compréhension de la façon dont les anormalités se produisent. Conséquemment, nous nous intéressons au rôle de l’acide polysialique (PSA) dans le développement des synapses GABAergiques. PSA est un homopolymère de chaînons polysialylés en α-2,8, et est exclusivement lié à la molécule d’adhésion aux cellules neuronales (NCAM) dans les cerveaux de mammifères. PSA est impliqué dans plusieurs processus développementaux, y compris la formation et la plasticité des synapses glutamatergiques, mais son rôle dans les réseaux GABAergiques reste à préciser. Les données générées dans le laboratoire du Dr. Di Cristo démontrent que PSA est fortement exprimé post- natalement dans le néocortex des rongeurs, que son abondance diminue au cours du développement, et, faits importants, que son expression dépend de l’activité visuelle i et est inversement corrélée à la maturation des synapses GABAergiques. La présente propose de caractériser les mécanismes moléculaires régulant l’expression de PSA dans le néocortex visuel de la souris. Les enzymes polysialyltransférases ST8SiaII (STX) et ST8SiaIV (PST) sont responsables de la formation de la chaîne de PSA sur NCAM. En contrôlant ainsi la quantité de PSA sur NCAM, ils influenceraient le développement des synapses GABAergiques. Mon projet consiste à déterminer comment l’expression des polysialyltransférases est régulée dans le néocortex visuel des souris durant la période post-natale; ces données sont à la fois inconnues, et cruciales. Nous utilisons un système de cultures organotypiques dont la maturation des synapses GABAergiques est comparable au modèle in vivo. L’analyse de l’expression génique par qPCR a démontré que l’expression des polysialyltransférases diminue au cours du développement; une baisse majeure corrélant avec l’ouverture des yeux chez la souris. Nous avons de plus illustré pour la première fois que l’expression de STX, et non celle de PST, est activité-dépendante, et que ce processus requiert l’activation du récepteur NMDA, une augmentation du niveau de calcium intracellulaire et la protéine kinase C (PKC). Ces données démontrent que STX est l’enzyme régulant préférentiellement le niveau de PSA sur NCAM au cours de la période post-natale dans le cortex visuel des souris. Des données préliminaires d’un second volet de notre investigation suggèrent que l’acétylation des histones et la méthylation de l’ADN pourraient également contribuer à la régulation de la transcription de cette enzyme durant le développement. Plus d’investigations seront toutefois nécessaires afin de confirmer cette hypothèse. En somme, la connaissance des mécanismes par lesquels l’expression des ii polysialyltransférases est modulée est essentielle à la compréhension du processus de maturation des synapses GABAergiques. Ceci permettrait de moduler pharmacologiquement l’expression de ces enzymes; la sur-expression de STX et/ou PST pourrait produire une plus grande quantité de PSA, déstabiliser les synapses GABAergiques, et conséquemment, ré-induire la plasticité cérébrale. / The functioning of the cerebral cortex requires coordinated action of two major neuronal subtypes - the glutamatergic projection neurons and the GABAergic interneurons. GABAergic interneurons represent 20 to 30% of all cortical cells. Even though they are a minor cell population in the cerebral cortex compared to glutamatergic neurons, they are key modulators of network dynamics and plasticity of neocortical circuits. It is therefore not surprising that aberrant development of GABAergic circuits is implicated in many neurodevelopmental disorders including epilepsy, Rett syndrome and schizophrenia. Understanding the molecular mechanisms governing the development of GABAergic inhibitory synapses in neocortex is important towards a better comprehension of how abnormalities in this developmental process can occur. Therefore, we focus specifically on the role of polysialic acid (PSA) in the development of GABAergic synapses. PSA is a α-2,8 polysialylated homopolymer, which is exclusively linked to the Neural Cell Adhesion Molecule (NCAM) in the mammalian brain. It is involved in several developmental processes including formation and plasticity of glutamatergic synapses; however its role in GABAergic circuit formation has not been explored so far. Previously in Dr Di Cristo’s lab, we showed that PSA is strongly expressed post-natally and its expression steadily declines during development in mice neocortex. We also showed that the developmental and activity-dependant regulation of PSA expression is inversely correlated with the maturation of perisomatic GABAergic innervation. Our aim is to characterize the molecular mechanisms regulating PSA expression in mouse iv visual cortex during post-natal development. Two polysialyltransferases, ST8SiaII (STX) and ST8SiaIV (PST), are responsible for PSA attachment to NCAM. By controlling the amount of PSA on NCAM, they can influence GABAergic synapses development. The mechanisms regulating STX and PST expression is crucial but remain still unknown. My research project focused on the mechanisms regulating STX and PST transcription in the mouse postnatal cortex. We used an organotypic culture system, which recapitulates many aspects of GABAergic synapse maturation as observed in vivo. Polysialyltransferases transcript levels were measured by qPCR and showed that STX and PST mRNA levels steadily decline during post-natal development in the mouse cortex; the sharpest reduction in the expression of both enzymes correlate with eye opening. We further demonstrate for the first time that STX mRNA levels is activity-dependant, requires the activation of NMDA receptors, an increase in intracellular Calcium levels and is PKC-dependent. Altogether, we show that the regulation of the expression of STX is the main mechanism responsible for PSA expression levels in the cortex around eyes opening. We next investigated whether epigenetic mechanisms regulate STX transcription and preliminary data suggest that histone acetylation and DNA methylation may contribute to STX expression during development. However, further experiments are required to confirm this hypothesis. In summary, understanding the mechanisms modulating STX and PST expression in the neocortex is essential for the comprehension of their precise role in GABAergic synapse maturation. This knowledge could allow us to modulate pharmacologically the expression of these enzymes; in turn overexpression of STX and PST may re-induce PSA expression, thereby destabilizing GABAergic synapses, and ultimately facilitating cortical plasticity in the adult.

Les Sémaphorines de classe 3 modulent de nombreux comportement neuritiques lors de la formation du système nerveux central. Leur liaison sur des complexes récepteurs composés de la sous unité obligatoire de liaison au ligand, les Neuropilines1,2 (Nrp1,2) et de la sous unité de signalisation, les PléxinesA1-4, permet d'assurer la spécificité fonctionnelle. Cependant, les mécanismes moléculaires contrôlant la formation de ces complexes récepteurs ne sont pas connus. Au cours de ma thèse, j'ai étudié l'assemblage des complexes récepteurs des Sémaphorines de classe 3 par une approche FRET. J'ai pu montrer que Nrp1,2 forment des homo et hétéro-oligomères à la membrane plasmique. Nrp1 peut former des hétero-oligomères avec les PléxinesA1,2 et 4 mais apparemment pas avec PléxineA3. La délétion du domaine Séma de PléxineA3 (PléxinesA3∆sem) suffit pour induire la formation d'hétéro-complexes Nrp1-PléxinesA3∆sem. Ces résultats suggèrent que le domaine Séma de PléxineA3 adopte une conformation différente des autres PléxinesA et empêche l'interaction entre PléxineA3 et Nrp1. De plus, toutes les PléxinesA peuvent former des homo-oligomères de manière indépendante du domaine Séma. Ces résultats suggèrent que les récepteurs des Sémaphorines de classe 3 pourraient former des complexes oligomériques plus important, composés d'homo-dimères de Nrps et de PléxinesA. Dans la deuxième partie de ma thèse, j'ai étudié la spécificité de signalisation des PléxinesA dans les interneurones GABAergiques du cervelet. Au laboratoire, nous avons montré que Séma3A induit la formation de branches des interneurones GABAergiques du cervelet par l'intermédiaire de Fyn. Mais l'identité des complexes récepteurs Séma3A impliquée dans ce processus n'était pas connue. Nous avons montré que les interneurones GABAergiques expriment PléxineA1,A2 A3 mais pas A4. Alors que les PléxinesA1,2 et 3 interagissent avec la protéine Fyn, seule l'activation des voies de signalisation de PléxineA1 et A2 induit la formation de branches in vitro. De manière intéressante, Fyn interagit avec les PléxinesA1 et A2 via son domaine SH3 alors qu'elle utilise son domaine SH2 pour l'interaction avec PléxineA3, suggérant l'importance du mode d'interaction de Fyn avec les PléxinesA pour sa fonction. Enfin nous avons pu montrer que PléxineA1 est la seule Pléxine in vivo capable d'induire un défaut de formation de branches des interneurones GABAergiques du cervelet. / Secreted class 3 Semaphorin (Sema3) modulates a wide variety of axon behavior during central nervous system formation. Sema3 family functions are triggered through binding to specific receptor complexes that include the obligate binding subunit Neuropilins-1 and 2 (Nrp1-2) and the signalling subunit plexin-A1-4. Yet, the exact mechanism controlling Sema3 receptor complex formation is not known. Here, we investigate Sema3 cell surface receptor formation using a time resolved FRET approach. We showed that Nrp-1 and 2 formed homo and hetero-oligomers at the cell surface of leaving cells. Nrp-1 can form hetero-oligomers with PlexinA1, A2 and A4 but not with PlexinA3. Deletion of the Plexin-Sema domain of PlexinA3 (PlexinA3∆sem) induced the formation of Nrp1 and PexinA3∆sem hetero-complexes. These results showed that PlexinA3-sema domain adopts a different conformation from the other PlexinAs and inhibited the interaction with Nrp1. Furthermore, PlexinAs can form homo-oligomers independently of the Plexin-Sema domain. These results further suggest that Sema3 receptors could form higher oligomeric complex that include homodimers of both neuropilins and PlexinAs. Understanding the basic principles of Sema3 receptor assembly will be pivotal to decipher how ligand binding translates into specific pathways of cellular signaling. In the second part of my thesis we investigated PlexinA specific signaling in cerebellar GABAergic interneurons. Sema3A induced GABAergic axonal branching in cerebellar cortex in a Fyn dependent manner (Cioni et al.,2013). However the identity of Sema3A receptor complexes involved in this process needed further investigation. We showed that PlexinA1, A2 and A3, but not PlexinA4, are expressed in GABAergic interneurons. While PlexinA1-3 are associated with FYN, only PlexinA1 and A2 induced axon branching. Interestingly, Fyn interaction with PlexinA1 and A2 is mediated via the SH3 domain while the interaction with PlexinA3 is through the SH2 domain, suggesting that the binding mode of Fyn to PlexinA is important. These results were further supported by in vivo characterization of PlexinA1-4 deficient mice that showed GABAergic axon branch deficit only in PlexinA1 mutant.